Navigation Links
IKARIA(R) to In-License BioLineRx's BL-1040
Date:7/6/2009

in acute care settings makes it an ideal party to further develop and bring BL-1040 to the global market."

About BL-1040

BL-1040 was invented by Professor Smadar Cohen from Ben-Gurion University and Professor Jonathan Leor from Tel-Aviv University. BioLineRx in-licensed the technology in 2005 from Ben-Gurion University through B.G. Negev Technologies and Applications Ltd. BL-1040 is currently in a Phase I/II pilot study in Germany and Belgium to determine the safety and feasibility of BL-1040 to treat AMI. Final results are anticipated in Q4 2009.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America and Australia. INOmax is approved for marketing in Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOmax, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE: BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's leading programs are BL-1020 for the treatment of schizophrenia an
'/>"/>

SOURCE Ikaria Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
2. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
3. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... Morton Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) ... at the Pennsylvania Convention Center, starting Saturday, April 18, ... The AACR holds claim to title of the oldest ... several journals, provides fellowships and grants, and partners with ...
(Date:4/16/2015)... The Council for Agricultural Science ... Borlaug CAST Communication Award goes to Dr. Channapatna ... in Alabama. Award nominees must demonstrate an ability ... the use of television, radio, or other social ... a specialist in the field of plant genetics ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2Regis Technologies Joins American Association for Cancer Research Annual Meeting 2The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... Assets, Talent, ANN ARBOR, Mich., Nov. 29 ... state of Michigan through the 21st Century,Jobs Fund. The ... loan,fund with a low interest rate, is intended to ... region. Job creation is vital for,consideration for approval of ...
... Nov. 29 As part of an ongoing ... maximize commercial,impact of their products, Premier Research Group ... industry-leading expertise in its core,service areas into a ... expertise within the group closely matches Premier Research,s ...
... Protalix,BioTherapeutics, Inc. (Amex: PLX ), today announced that ... on December 24, 2007, as the record,date for shareholders ... the,Company,s 2007 Annual Meeting of Shareholders. It is currently ... be held on,January 31, 2008, in Tel Aviv, Israel., ...
Cached Biology Technology:Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund 2Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund 3Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research 2Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders 2Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders 3
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... coactivators control the process by which a single gene ... called alternative splicing, said Baylor College of Medicine researchers ... the journal Molecular Cell. "A major question in biology ... at least 120,000 proteins," said Dr. Bert O'Malley, chair ...
... Starvation, malnutrition and re-feeding can have deadly consequences for ... frog. , PhD student Rebecca Cramp from The University ... can't digest food after long periods of starvation, the ... percent more effectively after 3 months without food, than ...
... immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) ... and non-Hodgkin lymphoma, according to a new study ... of the National Cancer Institute. , Studies of ... increased risks of several cancers, including Kaposi sarcoma, ...
Cached Biology News:Controlling protein diversity 2A frog's life is food for thought 2A frog's life is food for thought 3Antiretroviral therapy may prevent excess risk of some cancers in people with HIV 2
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
Biology Products: